Drugs / Transgenic Lymphocyte Immunization Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00061035 | Apr 2003 → ? | prostate neoplasm | Cosmo Bioscience | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Transgenic Lymphocyte Immunization Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00061035 ↗ |
| Known as | TLI | “Transgenic Lymphocyte Immunization Vaccine (TLI)” NCT00061035 ↗ |
| Modality | Cell therapy | “Transgenic cells are then returned to the patient to produce an immune response targeted at cancer cells expressing telomerase.” NCT00061035 ↗ |